Esomeprazole Prevents Aspirin-Induced Ulcers

This feature requires the newest version of Flash. You can download it here.
This feature requires the newest version of Flash. You can download it here.

This is the Medscape Medical Minute. I'm Dr. George Lundberg.

Long-term low-dose aspirin is commonly used to prevent cardiovascular events, but it produces its own risks, gastroduodenal ulcers, and esophagitis. Twelve investigators from Australia report in TheAmerican Journal of Gastroenterology in 2008[1] the results of a randomized, placebo-controlled trial of 20 mg daily of esomeprazole in 991 such patients at risk. Endpoints were recognition of gastric and duodenal ulcers, esophageal lesions, and associated symptoms. Over a 26-week period of study, 5.4% of the placebo group and only 1.6% of the treatment group developed ulcer disease while 18.3% and only 4.4%, respectively, developed erosive esophagitis and related symptoms. These differences are significant. Daily esomeprazole does help prevent these adverse GI effects in a population of long-term takers of low-dose aspirin.

This article is selected from Medscape Best Evidence.[2] I'm Dr. George Lundberg.

Reader Comments on: Esomeprazole Prevents Aspirin-Induced Ulcers
See reader comments on this article and provide your own.

Readers are encouraged to respond to Peter Yellowlees, MD, Deputy Editor of The Medscape Journal of Medicine, for the editor's eyes only or for possible publication as an actual Letter in the Medscape Journal via email:


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.